OBodies

OBodies

Antibody drugs and diagnostics have changed the face of modern medicine, yet their high development costs, complex manufacturing processes and relatively poor stability restrict their potential. OBodies are a new class of high-specificity binding protein with several important advantages over the conventional antibody approach. OBodies' novel platform technology is based on a small, ubiquitous protein domain, the OB-domain. In nature, the OB-domain has evolved as a highly flexible binding domain, found in a wide variety of functional roles. We are able to exploit this natural flexibility, by selecting a candidate domain from the appropriate organism and engineering high target specificity and affinity. Proprietary libraries based on human and thermophillic bacterial OB-domains are under development for human therapeutics and diagnostics, respectively.

Objective

WaikatoLink is seeking investment and partnerships with industry to further develop the technology and take to market.

Unique Selling Propositions
  • Broad range of applications due to small size
  • High stability meaning Obodies don't require refrigeration like antibodies do
  • Significantly smaller than traditional antibodies and antibody fragments
Applications
  • Research tools
  • Clinical diagnostics
  • Point-of-care diagnostics
  • Medical therapeutics
Project Status

Proof of Principle - Laboratory demonstration of principle only